In a major financial turnaround that has captured the attention of the animal health market, Hester Biosciences Limited—one of India’s leading veterinary biologicals and therapeutics manufacturers—officially released its audited financial results for the fourth quarter (Q4) and the full fiscal year ending March 31, 2026 (FY26).
The corporate filing, submitted to the stock exchanges, reveals an unprecedented surge in profitability. The company’s strategic pivot BACK TO its core competence of high-margin poultry diagnostics and vaccines has yielded dramatic results, prompting the Board of Directors to recommend a substantial dividend (110%) for its shareholders.
The Financial Metrics: A Historic Quarter
The standalone and consolidated balance sheets for the animal healthcare major indicate robust growth across key operational parameters:
-
Quarterly Profit After Tax (PAT): For Q4 FY26, Hester recorded an impressive 974% year-over-year increase in consolidated net profit, skyrocketing to ₹16.55 Crore, up from a meager ₹1.54 Crore in the corresponding quarter of the previous fiscal year (Q4 FY25)
-
Full-Year Profitability: The full-year consolidated net profit nearly doubled, posting a 99% operational growth to reach ₹57.48 Crore, compared to ₹28.92 Crore in FY25
-
Consolidated Revenue: Total revenue from operations for the quarter grew by 19%, stopping at ₹84.45 Crore, while the full-year revenue scaled up to ₹324.22 Crore
-
Shareholder Rewards: Riding on this wave of high cash generation, the Board recommended a final dividend of ₹11 per equity share (110%) for FY26, subject to upcoming shareholder approval at the Annual General Meeting
Sector Analysis: Poultry Surges While Ruminants Lag
The internal dynamics of Hester’s product divisions reveal a clear contrast in the current Indian animal health ecosystem:
1. The Poultry Healthcare Division (The Growth Engine)
The primary driver behind the massive Q4 turnaround was a phenomenal 41% growth in poultry segment sales. This was propelled by the timely commercialization of next-generation avian biologicals.
Crucially, management confirmed that Hester has secured the manufacturing and marketing licenses for its highly anticipated H9N2 Avian Influenza inactivated vaccine. This addition expands Hester’s biologicals portfolio at a time when poultry farms across South Asia are facing sustained seasonal disease pressures from suspected HPAI.
2. The Animal Healthcare Division (Ruminant Segment Drag)
In contrast to the poultry boom, Hester’s large-animal (cattle, sheep, and goat) therapeutics division experienced a 32% decline over the fiscal year. Company executives explicitly tied this drop to ongoing administrative and rolling tender delays within state and central government-backed institutional immunization programs, such as the National Foot and Mouth Disease (FMD) and Brucellosis eradication campaigns.
International Operations and Outward Expansion
Hester’s global manufacturing footprint showed a steady, defensive performance throughout the fiscal year:
-
Hester Africa: The company’s specialized manufacturing plant in Tanzania recorded a 12% revenue increase in local currency terms, driven by expanding distributions of its Peste des Petits Ruminants (PPR) and Contagious Bovine Pleuropneumonia (CBPP) vaccines across the African continent.
-
Hester Nepal: The automated facility in Nepal maintained its role as a key exporter of regulatory-grade vaccines, supporting international disease control tenders managed by global health bodies.
Market Sentiment and Future Outlook
The Q4 FY26 earnings release triggered an immediate positive response on the bourses, with Hester’s stock surging over 15% in intraday trading following the filing. Institutional investors are viewing this report as validation that Hester’s core manufacturing margins have successfully recovered from the post-pandemic raw material inflation that impacted earlier fiscal years.
Moving forward into the new financial year of 2026-27, the company’s growth strategy centers on expanding its private-market retail presence for cattle and pet supplements to reduce its heavy dependence on volatile government tender cycles and consolidate its success in poultry vaccines.
